“Overpowered” studies due to GLs [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2014-09-28 03:13 (4280 d 00:43 ago) – Posting: # 13603
Views: 20,122

Hi Khaoula,

❝ for minimum number of subject: it's not about possible significant treatment effect with low nuber of subject, low CV?


Likely. Let’s assume a 2×2 cross-over, T/R-ratio 0.95, n=12. For any CV ≤15.63% power will be >80%, for CV ≤13.39% >90%, for CV ≤9.85% >99%, etc. etc.
The lowest CVs I have seen so far were 5–7% (AUCs of valproic acid, methylphenidate). If you perform a study with a drug showing a CV of 6% in 12 subjects, power will be 99.99993%. In other words, a significant treatment effect is highly probable. See this presentation (slide 9): The red diamonds are sample sizes to reach at least 80% power. If you keep the sample size at 12 for low CVs, power will increase extremely (blue line).

BTW, the minimum sample size of 12 is arbitrary; some tables1,2 go down to 4.


  1. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharm Ther Toxicol. 1991;29(1):1–8. PMID 2004861.
  2. Hauschke D, Steinijans VW, Diletti E, Burke M. Sample Size Determination for Bioequivalence Assessment Using a Multiplicative Model. J Pharmacokin Biopharm. 1992;20(5):557–61. PMID 1287202.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
154 visitors (0 registered, 154 guests [including 27 identified bots]).
Forum time: 03:56 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5